Zoledronate and ibandronate treatments provide a significant improvement in BMD values in osteoporosis patients

Jaxon Dawson*, Drew Brody

Department of Orthopaedics, La Rabta Teaching Hospital Center, Tunis, 1007, Tunisia.

*Corresponding Author: Jaxon Dawson, Department of Orthopaedics, La Rabta Teaching Hospital Center, Tunis, 1007, Tunisia. E-mail: dawson.jaxon@gmail.com

Received date: October 10, 2018; Accepted date: October 25, 2018; Published date: November 13, 2018

Citation: Jaxon Dawson, “Zoledronate and ibandronate treatments provide a significant improvement in BMD values in osteoporosis patients”, J. Orthopaedics and Surgical Sports Medicine. DOI: http://dx.doi.org/10.31579/josm.2018/0012

Copyright: © 2018 Jaxon Dawson. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: In this study, we aimed to make a comparative analysis of short term clinical effectivity and side effects of intravenous zoledronate administration as single dose yearly and intravenous ibandronate administration as four doses per year.

Methods: The patients whom were included in our study had osteoporosis according to WHO criteria and were treated with either parenteral zoledronate or ibandronate. 43 patients were treated with single dose of 5mg intravenous zoledronat which was applied once in a year, whereas in 39 patients were treated with 3 mg intravenous ibandronate which was applied four times in a year in three months intervals. Biochemical tests were performed in all patients before intravenous drug infusion. Side effects during drug administration and also in the first three months of the treatment were noted for all patients. Clinical effectivity was analyzed according to changes in bone mineral density (BMD) at the end of two year after treatment.

Results: Eighty-two patients who were followed-up and evaluated for the effectivity and side effects of the treatment were included in our study. The compliance of patients were 100% in both groups. Mean age was 75.2±6.9 years and mean body mass index (BMI) was 25.9±7.2. In zoledronate group in which there were 23 females and 20 males. Mean age was 73.6±8.7 years and mean BMI was 27.3±4.4. In ibandronate group in which there were 39 females. There were no statistically significant differences between the groups in terms of gender (p=0.009) Mean age, BMI and rate of diagnosed side effects were not statistically significant between the groups. According to a one-year follow-up in both groups comparison with before application had a statistically significant increase in BMD (p<0.01). However, a one-year follow-up between the two groups in terms of mean values of bone mineral density did not differ significantly (p>0.05).

Conclusion: Choice of medical treatment is decided according to bone mineral density and personal risk factors in osteoporosis. Parenteral agents in the treatment of osteoporosis may be the preferred choice for the patients with comorbid diseases, using multiple drug therapies, or having trouble in using oral drug therapy. However, it should always be kept in mind that drug related side effects may be seen more commonly with parenteral agents. Clinicians should be aware of the probable side effects during and after application.

Keywords: Osteoporosis, treatment, zoledronat, ibandronate, effectivity, side effects

Introduction

Osteoporosis (OP) is a systemic metabolic bone disease which is characterized by low bone mass and deterioration of bone microarchitecture, resulting in increased susceptibility to fractures [1]. The world health organization (WHO) reported that nearly 30% of women over 50 years of age have osteoporosis and increased risk of fractures, while one eightths of men carry risk of fracture [2]. Femoral neck fractures related to vertebral and distal radius fractures are most commonly observed in patients with osteoporosis [3]. Applications for prevention, diagnosis and treatment of OP may prevent fractures and its sequelae [4]. However, today, a completely safe, effective and generally accepted treatment for OP has not been defined yet [5].

Medications preventing bone resorption or increasing bone formation are used alone or in combination during the treatment [6]. Bisphosphonates (BF), which are widely used in the treatment of osteoporosis, are connected to hydroxyapatite in bone, provide resistance to the action of pyrophosphatases, reducing bone resorption [7]. In addition, they show action by changing the properties of the bone matrix responsible for the activation of osteoclasts, affecting the formation of osteoclast from progenitor cells, and by inhibiting the function of mature osteoclasts [7,8].

In the case of oral bisphosphonates, there can be upper gastrointestinal (GI) side effects, acute phase reaction, hypocalcemia and secondary hyperparathyroidism, musculoskeletal pain, osteonecrosis of the jaw and eye complaints [5,9]. Where as in the case of intravenous bisphosphonates (zoledronic acid, etc.) used to treat osteoporosis, all of the side effects mentioned above may develop, other than upper GI complaints. Renal toxicity, though less, may develop in the case of zoledronate [5,9].

In this study, the aim was to compare early period side effects and short-term action of a single dose per year of zoledronate administered as an intravenous infusion and ibandronate therapy which is applied 4 times per year.

Materials and methods

82 patients admitted to our outpatient orthopedics clinic and diagnosed with osteoporosis according to WHO criteria were included in our study. The patients were asked for getting information about on their age, height, weight, number of pregnancies, smoking and alcohol use, medication use history and whether they have any additional disease or not. Ibandronate is indicated only in using of the treatment, for patients who postmenopausal Osteoporosis or Osteoporotic women in our country.
Thus Male Patients were used only Zolendronate. Consequently the patients were not randomized. Clinical evaluations, radiologic images, blood parameters and bone mineral density measurements of patients for a diagnosis of osteoporosis were recorded. The patients were divided into two groups as the group receiving parenteral zoledronate therapy (Group 1, n=43) and the group receiving ibandronate therapy (Group 2, n=39). 5 mg zoledronate was administered to the patients in Group 1 as an intravenous infusion for 15 minutes once a year, and IV ibandronate was administered to the patients in Group 2 as an intravenous infusion once every quarter of a year under hospital conditions. In order to investigate the effectiveness of treatments applied to these patients with a T-score of -2.5 and below, their bone mineral density (BMD) values were evaluated at the end of a two year follow-up period. Their values before and after drug administration were considered, and any side effects developed during and at the end of treatment were recorded.

Statistical analysis

SPSS 11.0 for Windows (SPSS Inc. Chicago, IL) statistical analysis software was used for the statistical calculations. Normal distribution of our data was evaluated using Kolmogorov-Smirnov test. Afterwards, T-test for comparison of demographic data and the test for the comparison of categorical data were used. On the other hand, Mann-Whitney U test was used for as compared to baseline vertebral and hip BMD and T scores between groups. Wilkonson Signed Rank Test for delta change before-after treatment in groups were used. P values less than 0.05 were considered statistically significant. The results are expressed as the mean±standard deviation or median (25 and 75 percentile).

Results

A total of 82 patients who were observed and questioned about side effects during and at the end of the administration were included in the study, and the mean follow-up time was 26 months. The compliance of patients were 100% in both groups. In Group 1 treated with zoledronate, mean age of 43 patients was 75.23±6.9 and their mean body mass index (BMI) was 26.94±7.2. Of these patients, 23 were women (54%) and 20 were men (46%). In Group 2 treated with ibandronate, mean age of 39 patients was 73.64±8.7 and their mean BMI was 27.34±4.4. Of all these patients were women. A statistically significant difference was existed between the groups in terms of gender (p=0.000). However, there was no statistical difference in terms of age, BMI and rate of observed side effects (Table 1). In zoledronate group, gastrointestinal system (GIS) side effects were detected in 3 patients and acutephase reaction (APR) was detected in 2 patients, while in ibandronate group, GIS side effects were detected in one patient and side effects including APR were detected in another patient.

| Parameter            | Group 1 (zoledronat) | Group 2 (ibandronat) | P value |
|----------------------|----------------------|----------------------|---------|
| Age (years; mean±ss) | 75.23±6.9            | 73.64±8.7            | 0.358*  |
| Body mass index      | 26.94±7.2            | 27.34±4.4            | 0.762*  |
| Gender               | 23/20                | 39/0                 | <0.05** |
| Side effect (There is/not) | 5/38                | 2/37                 | 0.293** |

Group 1 as compared to baseline vertebral and hip BMD and T scores had improvement significantly after treatment. Likewise .

| Variable            | Group 1 n=43 | Group 2 n=39 | P**   |
|---------------------|--------------|--------------|-------|
| Vt                  | -2.50 (-2.90/-1.50) | -2.90 (-3.30/-2.50) | 0.008 |
| Vt2                 | -1.80 (-2.40/-1.10) | -2.00 (-2.60/-1.20) | 0.440 |
| delta change        | 0.20 (-0.31/0.09)  | -0.30 (-0.50/-0.16) | 0.020 |
| p*                  | <0.001       | <0.001       |       |
| Vbmd                | 0.79 (0.71/0.89)  | 0.81 (0.73/0.87)  | 0.963 |
| Vbmd2               | 0.83 (0.80/0.91)  | 0.89 (0.82/0.93)  | 0.052 |
| delta change        | 0.02 (0.01/0.16)  | 0.11 (0.01/0.24)  | 0.060 |
| p*                  | <0.001       | <0.001       |       |
| Ht                  | 2.50 (-2.80/-1.50) | -2.50 (-3.20/-1.60) | 0.268 |
| Ht2                 | 1.60 (-2.10/-1.00) | -1.60 (-2.50/-1.00) | 0.838 |
| delta change        | 0.29 (-0.39/-0.16) | -0.36 (-0.52/-0.11) | 0.240 |
| p*                  | <0.001       | <0.001       |       |
| Hbmd                | 0.80 (0.74/0.90)  | 0.73 (0.67/0.83)  | 0.008 |
| Hbmd2               | 0.88 (0.80/0.92)  | 0.87 (0.81/0.96)  | 0.707 |
| delta change        | 0.07 (0.01/0.15)  | 0.21 (0.02/0.42)  | 0.001 |
| p*                  | <0.001       | <0.001       |       |

Table 2 : Comparison of t score and bone mineral density t score according to the groups.

On the other hand, in both groups, as compared to baseline post-treatment vertebral & hip BMD and post-treatment vertebral & hip T scores were not significantly difference between the groups (Table 2).

There was significant difference between groups in compared of Vt delta changes and the amount of improvement was greater in group 2. Also there was significant difference between groups in compared of Hbmd delta changes and the amount of improvement was greater in group 2 (Table 2).

Discussion

The most widely used method for screening and diagnosis of osteoporosis is the measurement of bone mineral density (BMD) in the hip and lumbar region by central Dual-energy X-ray absorptiometry (DXA). According to WHO diagnostic criteria, -2.5 and below cause a diagnosis of osteoporosis [10,11]. Treatment indications were established by National Osteoporosis Foundation (NOF) as a T-score of -2.5 or below in postmenopausal women and men aged 50 years and above, presence of a hip or vertebral fracture, fracture history in conjunction with low bone density (T score in the range of –1 and –2.5), presence of secondary causes increasing fracture risk related to low bone density, low bone density and a 10-year hip fracture risk of 3% or above or 10-year fracture risk of 20% or above according to FRAX scoring [12,13].

In medical treatment OP; bisphosphonates, strontium, teriparatide, selective estrogen receptor modulator (SERM) and calcitonin are used. Bisphosphonates are the antiresorptive agents which are most commonly used to treat OP and reduce the risk of hip fracture in the elderly patients mostly. Even after bisphosphonates are discontinued, their positive effects on bone are maintained and they are the best agents to prefer in senile and male OP [5,12,14,15]. Based on these, we planned this study to compare the effects and possible side effects on bone mineral density of two bisphosphonate medications used to treat osteoporosis.

Bisphosphonates are safe and well tolerated drugs used in the treatment of osteoporosis and a number of side effects may occur depending on their use. These are usually upper gastrointestinal system (GIS) and acute influenza-like symptoms. Upper gastrointestinal symptoms usually appear during oral bisphosphonate therapy, while temporary influenza-like symptoms frequently appear during IV administration of nitrogen-containing bisphosphonates (pamidronate, ibandronate, zoledronic acid) [16-18]. Eye-related side effects were also reported [19]. In a study in which risedronate was investigated, 3 years after treatment the incidence of GIS side effects was found as 27%, while this percentage was reported as 26% in the placebo group.
In the case of 5-year results, it was demonstrated that the placebo group with 13.8% caused greater incidence of GIS side effects compared to the risedronate group with 12.6% [20]. Similar results were also reported for ibandronate in BONE study [21]. On the contrary, in the HORIZON study [22], patients treated with zoledronic acid were reported to suffer from GIS side effects, including nausea (8.5% and 5.2%), vomiting (4.6% and 3.2%), diarrhea (6% and 5.6%), upper abdominal pain (4.6% and 3.1%) and dyspepsia (4.3% and 4%), compared to the placebo group.

Acute phase reaction (APR) is characterized by low-grade fever, myalgia, arthralgia, and headache. This influenza like symptoms generally occur within three days of drug administration and symptoms usually resolve 2-3 days of administration and may last for 7-14 days [16,23]. Symptoms which appear at a rate of 10% after IV administrations may also be observed in oral applications if adequate dosage is reached. In the HORIZON study [24], acute phase reaction symptoms were found significantly high in zoledronic acid group, compared to the placebo group (31.6%, 6.2%, respectively). High BF blood concentrations reached during IV treatments may cause acute renal problems. This effect could not be shown in therapeutic doses of oral BFs [25]. Still, in patients with a creatinine clearance lower than 30 ml/min, it is appropriate for avoiding using either oral or parenteral BF because there isn’t enough clinical experience. In studies carried out on the subject, alendronate [26], risedronate [27] and ibandronate [28] were shown to have renal side effects similar to those of placebo. It was reported that mild and transient serum creatinine level appearing on day 9 and 11, resulting from use of zoledronic acid in osteoporosis treatment, is not permanent at the end of 3 years, and that renal side effects are comparable to placebo [9,24]. In a study conducted using 5 mg zoledronate in postmenopausal osteoporosis patients, atrial fibrillation risk was found to be high, however, it was concluded in subsequent studies that such an increased risk does not exist [24,30]. Osteonecrosis of the jaw can be seen in cancer patients while they are using highly dose iv pamidronate or zoledronic acid [9].

In our study, APR-like findings were observed in 3 patients (8%) and GIS side effects were detected in 2 patients (5%) from zoledronate group. While in ibandronate group, GIS side effects were observed in one patient (2.7%) and APR-like side effects were observed in one patient (2.7%), which are less than those in the literature.

Zoledronate is the only FDA-approved agent used to prevent further fractures after an osteoporotic hip fracture. In the HORIZON-PFT study conducted to determine the effects of zoledronic acid in the case of postmenopausal osteoporosis, zoledronic acid was administered to 3881 patients at baseline, 12th and 24th months. The patients were on follow-up for 3 years and compared with placebo group. In that study, new vertebral fractures and hip fractures were considered as the primary endpoint. In zoledronic acid group, morphometric vertebral fracture risk and hip fracture risk decreased by 70% and 41%, respectively within 3 years [31]. HORIZON Recurrent Fracture Study covered patients with a mean age of 74.5 who have undergone surgery for osteoporotic hip fracture in the last 3 months, and rates of having new clinical fracture were taken into consideration as the primary target. The risk of having a new clinical fracture decreased by 35% in the group treated with zoledronic acid within an average of 19 months, compared to placebo. Zoledronic acid treatment also decreased the mortality rate by 28% [24,29]. In a study conducted on glucocorticoid-induced osteoporosis patients, it was observed that zoledronate treatment is more effective than risedronate treatment and it caused a higher increase in lumbar spine BMD after treatment than risedronate treatment. (Zoledronate 4.1%, Risedronate 2.7%) [32]. In an osteoporosis study by Voskaridou et al., on thalassemia patients, IV 4 mg zoledronate was administered to one group once every 6 months, IV 4 mg zoledronate was administered to another group once every 3 months and placebo treatment was applied to another once every 3 months for 1 year, and the patients who received IV 4 mg zoledronate once every 3 months were found to have higher lumbar spine BMD, whereas no such change was detected in the placebo group [33].

In one study, the patients who were followed-up with daily oral ibandronate of 2.5 mg were found to have a 52% reduced vertebral fracture risk and a 6.5% increased lumbar spine BMD [34]. In a DIVA (Dosing IntraVenous Administration) study, similar increase was observed in the case of double IV ibandronate treatment (3mg once every 3 months, 2mg once every 2 months) compared to baseline lumbar BMD (5.1% and 4.8%), and an increase of 3.8% was observed in lumbar BMD with daily oral 2.5 mg ibandronate treatment compared to baseline values [35]. In our study, in both groups as compared to baseline vertebral and hip BMD and T scores had improvement significantly after treatment (Table 2), and these values are similar to those reported in the literature.

We could not find any certain knowledge on the literature and also there is no consensus about how to follow up? And especially how and/or what way to measure the affectiveness of treatment? How much change is required for clinical significance? [11,14,36-46]. In the study, patients receiving bisphosphonate treatment causing a decline in BMD have a higher for osteopotic fracture risk compared with patients whose BMD increases [36]. In another study, it is reported that causes significant changes in fracture rate, even a small difference like as -0.025 on the basis of T-score [37]. In our study, delta changes for vertebral and hip T-score were in the range between 0.20-0.36 vertebral in both groups. Also delta changes for vertebral and hip BMD were in the range between 0.02- 0.21 in both groups (Table 2).

BMD and T-score in the assessment of osteoporotic fracture risk is important. However, it is not enough. When calculating the risk of fracture not only BMD but also bone turnover, bone architecture, bone strength as well as other factors must be considered. Osteopenic patients are at risk, such as patients with osteoporosis [38-40]. Current diagnosis and treatment decisions for osteoporosis must be depended on the fracture risk calculated based on the results of comprehensive diagnostic procedures [38,41,42]. Monitoring the effectiveness of osteoporosis treatment presents a challenge in everyday clinical practice. In general, the efficacy of the therapy is evaluated by comparing pre and post treatment BMD and/or T-score. As an alternative, BMD and T-score along with other parameters such as biochemical markers of bone turnover can be used to assess effectiveness of treatment in the osteoporotic patients [39,43-45]. In our study, we can mention reduced osteoporotic fracture risk because it’s a significant improvement after treatment compared to before treatment in both groups.

**Conclusion**

It was demonstrated in this study that zoledronate and ibandronate treatments provide a significant improvement in BMD values in osteoporosis patients and there is no significant difference between their efficacies and side effects. Parenteral treatment of osteoporosis is considered as a treatment option that provides high patient compliance in elderly osteoporotic patients with comorbid diseases taking several medications, and precautions should be taken against any side effects that may occur during and after intravenous administration.

**References**

1.  Tokgoz N, Akdeniz M, Ucar M, Kilic K and Celik A. Is quantitative magnetic resonance imaging valuable in the assessment of trabecular bone structure in osteoporosis? Eklem Hastalik Cerrahisi. 2013; 24:2-6.
2.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129.
3.  Johnell O and Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17:1726-33.
4.  Gallagher TC, Geling O and Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Intern Med. 2002; 162:450-6.
5.  Kanis JA, Burlet N, Cooper C, Delmas PD, Ringster JY, Borgstrom F and Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19:399-428.
6. Raisz LG. The osteoporosis revolution. Ann Intern Med. 1997; 126:458-62.
7. Aslan A, Sargın S, Özmeriç A and Yağcı Ş. Treatments of patients with postmenopausal osteoporosis: A comparative study. OA Musculoskeletal Medicine. 2014; 2:4.
8. Watts NB. Treatments of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 2001; 27:197-214.
9. Gomez Font R, Martínez Garcia ML and Olmos Martinez JM. Osteochoemoneerosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal. 2008; 13:E318-24.
10. Aslan A, Uysal E and Karakoyun Ö. Bone Mineral Density Value in Kastamonu and Area of Turkish Society Women. J Clin Anal Med. 2013; 4:209-12.
11. Aslan A, Karakoyun O, Guler E, Aydin S, Gok MV and Akkurt S. [Evaluation of bone mineral density, osteoporosis prevalence and regional risk factors in Turkish women living in Kastamonu: KASTURKOS study]. Ekem Hastalik Cerrahisi. 2012; 23:62-7.
12. National Osteoporosis Foundation. 2014.
13. FRAX WHO Fracture Risk Assessment Tool.
14. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2011; 71:65-78.
15. Gates BJ, Sonnett TE, Duvall CA and Dobbins EK. Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother. 2009; 7:293-323. [Article] PubMed
16. Recker RR, Lewiecki EM, Miller PD and Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009; 122:S22-32.
17. Solomon DH, Rekedal L and Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol. 2009; 21:363-8. [Article] PubMed
18. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010; 86:421-35. [Article] PubMed
19. Atik OS. What do we know about the ocular adverse effects associated with intravenous bisphosphonates? Ekem Hastalik Cerrahisi. 2011; 22:1.
20. Sorenson OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C and Reginster JY. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003; 32:120-6. [Article] PubMed
21. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC and Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19:1241-9.
22. Reclast R. (zoledronic acid) prescribing information. Stein, Switzerland: Novartis Pharma Stein AG; 2009.
23. Rizzoli R, Reginster JY, Boonen S, Breact G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA and Cooper C. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011; 89:91-104.
24. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Erskine EF and Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809-22. [Article] PubMed
25. Pazianas M, Cooper C, Ebetino FH and Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010; 6:325-43.
26. Sindel D. Osteoporosis Treatment at Present and in the Future. Turk J Phys Med Rehab. 2013; 59:330-7.
27. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A and Cummings SR. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007; 22:503-8. Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH and Russell RG. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater. 2010; 92:149-55.
28. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauksaiti D, Ward P, Sambrook P and Reid DM. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54:1838-46.
29. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsetten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF and Boonen S. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357:1799-809. [Article] PubMed
30. John Camm A. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther. 2010; 32:426-36.
31. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ and Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344:333-40.
32. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P and Sambrook PN. Zoledronic acid and risedronate in the prevention of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373:1253-63.
33. Voskaridou E, Anagnostopoulos K, Konstantopoulos K, Stoupas E, Spyropoulou E, Kiamouris C and Terpos E. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006; 91:1193-202.
34. Reginster J, Minne HW, Sorenson OH, Hooper M, Roux C, Brandi ML, Lund B, Ethen D, Pack S, Roumagnac I and Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11:83-91.
35. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauksaiti D, Ward P, Sambrook P and Reid DM. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54:1838-46.
36. Sebbâ AI. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther. 2008; 30:443-52. [Article] PubMed
37. Aslan A, Konya MN, Yağcı Ş and Karakoyun Ö. Is Turkish FRAX® Model Sufficient? The Analysis of Osteoporotic Fracture Risk In Turkish Population By Using FRAX® [Article in Turkish]. Turkish Journal of Osteoporosis. 2014; 20:21-25. [Pdf]
38. Baim S and Leslie WD. Assessment of fracture risk. Curr Osteoporos Rep. 2012; 10:28-41.
39. Ataoglu MB, Atik OS, Gul O, Sarikaya B, Gormeli G, Ozeturk BY and Ozgurol B. [A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment]. Ekem Hastalik Cerrahisi. 2013; 24:82-6.
40. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse RG, Prior JC, Kreiger N, Tenenhouse A and Goltzman D. Association between change in BMD and fragility fracture in women and men. J Bone Miner Res. 2009; 24:361-70.

41. Lorenc RS, Misiorowski W and Karczmarewicz E. Critical points in strategies for the diagnosis and treatment of osteoporosis. Endokrynol Pol. 2009; 60:124-33.

42. Gul O, Atik OS, Erdogan D, Goktas G and Elmas C. Transmission and scanning electron microscopy confirm that bone microstructure is similar in osteopenic and osteoporotic patients. Eklem Hastalik Cerrahisi. 2013; 24:126-32.

43. Meier C and Kraenzlin ME. [Osteoporosis: evaluation, diagnosis and monitoring]. Ther Umsch. 2012; 69:145-52.

44. Miller PD. Monitoring osteoporosis therapies. Curr Osteoporos Rep. 2007; 5:38-43.

45. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, Kreiger N, Tenenhouse A and Goltzman D. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ. 2008; 178:1660-8.